{
    "nctId": "NCT02623751",
    "briefTitle": "Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer",
    "officialTitle": "Phase 1 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Number and percentage of subjects with treatment-emergent adverse events including dose-limiting toxicities and serious adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women aged \u2265 20 and \\< 75 years at the time of consent;\n* Estrogen receptor positive and/or progesterone receptors positive;\n* HER2-negative\n* Nonresectable advanced or recurrent breast cancer previously treated with nonsteroidal aromatase inhibitor (AI), and planning to be treated with exemestane\n\nExclusion Criteria:\n\n* Radiation therapy or immuno therapy within 14 days before the first dose of investigational product;\n* Chemotherapy, biological medicines, other pharmacotherapy or major surgery within 21 days before the first dose of the investigational product;\n* Prior chemotherapies of \u2265 3 regimens for advanced or recurrent breast cancer;\n* Ongoing treatment with other investigational product",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}